Exelixis

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exelixis reports robust Q4 performance, eyes pipeline expansion in 2023

Exelixis showed strong revenue growth and strategic wins in Q4 2022.
The company faces challenges with net losses and gross to net expectations.
Opportunities lie in pipeline advancement, zanzalintinib development, and new business activities.
Overall, Exelixis remains focused on growth and innovation in the pharmaceutical sector.

Exelixis reports strong Q1 earnings, advances promising pipeline programs

Exelixis showcased robust financials and a promising pipeline in Q1, driven by strong CABOMETYX performance and R&D advancements.
Challenges include gross to net impact and delays in share repurchase program purchases, with key decisions pending on XL102 progress.
Opportunities lie in expanding Phase 3 trials, focusing on unmet needs, and maintaining a strategic approach to asset prioritization for future growth.

Exelixis reports robust Q2 earnings, advances pipeline for growth

Exelixis delivered a strong Q2 performance with significant revenue and income figures, driven by the success of CABOMETYX and ongoing R&D efforts.
The company's market leadership, legal resolution with Teva, and commitment to innovation position it well for future growth and competitive advantage.
While facing challenges in program decision-making and market penetration, Exelixis has opportunities in pipeline advancement, regulatory discussions, and investor engagement.
Overall, Exelixis remains focused on its mission to help cancer patients, with a positive outlook and strategic initiatives in place for continued success.

Exelixis reports strong Q3 earnings, faces guidance challenges and growth opportunities

Exelixis had a strong Q3 2023 with robust revenue growth from CABOMETYX and ongoing operational support.
The company faces challenges in financial guidance adjustments and questions on FDA expectations and legal proceedings.
Opportunities lie in potential growth for CABOMETYX, advancing pipeline assets, and expanding into new indications.
Overall, Exelixis remains focused on innovation, collaboration, and supporting cancer patients with upcoming R&D Day excitement.

Exelixis reports robust 2023 performance, eyes growth through collaborations

Exelixis had a strong financial performance in 2023, driven by the cabozantinib franchise and strategic initiatives.
While facing challenges such as access to therapies and treatment variations, the company is well-positioned for growth.
Opportunities lie in collaborations, regulatory progress, and innovative drug development, positioning Exelixis for future success.

Exelixis reports strong Q1 earnings, focuses on pipeline advancement

Exelixis had a robust Q1 2024 with revenue and demand growth for Cabozantinib franchise.
Company is focused on advancing new indications, returning capital to shareholders, and pipeline development.
Challenges include study criteria, market capture, and capital allocation decisions.
Exciting opportunities lie in Zanza's potential, new combinations, and market growth prospects.

Exelixis excels in Q2 with cabozantinib driving revenue growth

Exelixis delivered a strong Q2 performance driven by cabozantinib franchise. Despite challenges in a competitive landscape, the company's focus on pipeline assets and commercial success presents growth opportunities. With increased revenue guidance and strategic initiatives, Exelixis is poised for continued success.

Exelixis excels in Q3 2024 with revenue growth and increased guidance

Exelixis delivered a strong performance in Q3 2024, marked by revenue growth, profitability, and increased guidance for the full year. The company's financial stability, strategic focus on oncology, and strong cash position provide a solid foundation for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Exelixis Inc (NASDAQ: EXEL) has announced results demonstrating efficacy benefits of Cabometyx (cabozantinib) in patients with previously untreated advanced renal cell carcinoma (RCC), regardless of prior nephrectomy (surgical removal of a kidney) status. Data were shared at the 2021 European Society for Medical Oncology Congress (ESMO21).

Exelixis' Cabometyx Combo Trial Shows Benefit In Kidney Cancer Regardless Of Prior Surgery

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results demonstrating efficacy benefits regardless of prior nephrectomy status with CABOMETYX® (cabozantinib) in combination with Bristol Myers Squibb's OPDIVO® (nivolumab) versus sunitinib for patients with previously untreated advanced renal cell carcinoma (RCC). The data, from a post-hoc exploratory analysis of the phase 3 CheckMate -9ER pivotal trial, will be presented as an ePoster available on demand beginning

Exelixis Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on CheckMate -9ER Analysis Presented at ESMO 2021

A couple of months back we discussed that the stock price of Exelixis, a genomics-based pharmaceuticals company focused on oncology treatments, is best avoided after a negative outcome from its clinical trials for Cabometyx in previously untreated liver cancer patients resulted in a sharp drop in.

What's Happening With Exelixis Stock?

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Gisela M. Schwab, M.D., the company's President, Product Development and Medical Affairs and Chief Medical Officer, passed away over the weekend. Dr. Schwab had been on a medical leave of absence since June 18, 2021. Exelixis President and Chief Executive Officer Michael M. Morrissey, Ph.D., issued the following statement on behalf of the Exelixis team and the company's Board of Directors: “All of us at Exelixi

Exelixis Statement on the Passing of Two Senior Executives

This biotech stock is down, but it's not out just yet.

Is Exelixis Stock a Buy?

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at the following virtual investor conferences in September: Morgan Stanley 19th Annual Global Healthcare Conference: Exelixis is scheduled to present at 1:15pm EDT / 10:15am PDT on Thursday, September 9, 2021. H.C. Wainwright 23rd Annual Global Investment Conference: Exelixis' pre-recorded session will be available on-demand beginning 7

Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September

Takeda Pharmaceutical

Exelixis Inc's (NASDAQ: EXEL) collaborating partner Takeda Pharmaceutical Co Ltd (NYSE: TAK) and Ono Pharmaceutical Co Ltd have received approval for Cabometyx (cabozantinib) in Japan. The approval covers Cabometyx combined with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivi (nivolumab) for unresectable or metastatic renal cell carcinoma (RCC).

Exelixis - Takeda's Cabometyx Scores Approval In Japan For Kidney Cancer

Green Thumb Industries Inc.

Skillz

Tesla

Analysts' high-water price targets foresee these fast-growing stocks doubling or tripling in value.

4 Growth Stocks With 116% to 247% Upside, According to Wall Street

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX® (cabozantinib) in Japan, and Ono Pharmaceutical Co., Ltd. (Ono) received approval from the Japanese Ministry of Health, Labor and Welfare to manufacture and market CABOMETYX in combination with OPDIVO® (nivolumab) as a treatment for unresectable or metastatic renal cell carcinoma (

Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma

Agios Pharmaceuticals

Johnson & Johnson

Moderna

Novavax

SAGE Therapeutics

Vertex Pharmaceuticals

Biotech stocks are worth considering. Risk aside, big pharma firms can still produce big pharma returns at the end of the day.

7 Best Biotech Stocks to Buy in 2021 with Huge Upside

Exelixis (EXEL) expands collaboration with Invenra to include an additional 20 targets for multi-specific antibody, antibody-drug conjugate, and other biologic candidate discovery and development.

Exelixis (EXEL) Expands Oncology Collaboration With Invenra

Exelixis Inc (NASDAQ: EXEL) and Invenra have expanded their discovery and licensing collaboration to include 20 additional oncology targets. The augmented partnership builds on the ongoing collaboration and license agreement to discover and develop mono-specific and multi-specific antibodies.

Exelixis, Invenra Expand Oncology Pact

ALAMEDA, Calif. & MADISON, Wis.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Invenra, Inc. today announced that they have expanded their discovery and licensing collaboration to include an additional 20 oncology targets. The augmented partnership builds on the two companies' ongoing collaboration and license agreement to discover and develop mono-specific and multi-specific antibodies for incorporation into novel biologics to treat cancer, which was originally announced in May 2018 and e

Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology

Exelixis (EXEL) beats on both earnings and revenues in the second quarter. Both figures increase on a year-over-year basis.

Exelixis (EXEL) Beats on Q2 Earnings & Revenues, Ups Sales View

Exelixis, Inc. (EXEL) CEO Mike Morrissey on Q2 2021 Results - Earnings Call Transcript

Shares of Exelixis (NASDAQ:EXEL) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 48.00% year over year to $0.37, which beat the estimate of $0.07.

Recap: Exelixis Q2 Earnings

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2021 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones. “In the second quarter of 2021, Exelixis delivered a 59 percent year over year increase in CABOMETYX® net product revenue growth and record total revenues, based on the broad adoption of the CABOMETYX and OPDIVO® combination

Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update

The FDA has accepted Exelixis Inc's (NASDAQ: EXEL) supplemental marketing application seeking approval for Cabometyx (cabozantinib) for differentiated thyroid cancer (DTC). The application under priority review covers patients 12 years and older who have progressed following prior therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate).

Exelixis Files US Application For Expanded Use Of Cabometyx In Patients 12+ Years With Thyroid Cancer

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for CABOMETYX® (cabozantinib) as a treatment for patients 12 years and older with differentiated thyroid cancer (DTC) who have progressed following prior therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate). The FDA granted Priority Review designation and assigned a Pre

Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Annaly Capital

Trulieve Cannabis Corp.

These top-tier growth, value, and income stocks can build investor wealth, even with the market near an all-time high.

3 Top Stocks That'll Make You Richer in August (and Beyond)

Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Exelixis (EXEL) Q2 Earnings Expected to Decline

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2021 financial results will be released on Thursday, August 5, 2021 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the webcast link, log onto www.exelixis.com and proceed to

Exelixis to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021

Ford Motor Company

You don't need a lot of cash to begin or further your trek toward financial independence.

The Smartest Stocks to Buy With $20 in July

The market may have overreacted to weak clinical trial data, but its pessimism wasn't entirely misplaced.

After Plummeting More Than 23%, Is Exelixis a Buy?

The biotech stock plunged after disappointing clinical results.

News for Exelixis Stock (EXEL)